Impact of wide bandgap p-type nc-Si on the performance of a-Si solar cells

This paper reports the impact of a wide bandgap p-type hydrogenated nanocrystalline silicon (nc-Si:H) on the performances of hydrogenated amorphous silicon (a-Si:H) based solar cells. The player consists of nanometer-sized Si crystallites and has a wide effective bandgap determined mainly by the quantum size-confinement effect (QSE). By incorporation of this p-layer into the devices we have obtained high performances of a-Si:H top solar cells with V-infinity=1.045 V and FF=70.3 %, and much improved mid and bottom a-SiGe:H cells, deposited on stainless steel (SS) substrate. The effects of the band-edge mismatch at the p/i-interface on the I-V characteristics of the solar cells arc discussed on the bases of the density-functional approach and the AMPS model.

C-118 from fullerenols: Formation, structure and intermolecular nC(2) transfer reactions in mass spectrometry

In fast atom bombardment, two fullerenols C-60(OH)(x) (x=13-15) and C-60(OH)(x) (x-24-26) gave rise to a group of ions centered at C-118 with intervals of 24 mass units in the high mass region. In contrast, no such ions appeared in the mass spectra of pure C-60, C-70 and other fullerene derivatives such as C-60(C6H5)(10), under the same conditions. It is proposed that the pinacol rearrangement of C-60(OH)(2), resulting from partial rupture of the polyhydroxy molecules, produces C-59 with two carbon atoms bearing an unpaired electron, and that dimerization of this reactive intermediate is responsible for the formation of the predominant product C-118. An intermolecular nC(2) transfer process is used to explain the symmetrical abundance distribution of these product ions in the spectra of fullerenols.

A Phase I Clinical Study of Cisplatin-Incorporated Polymeric Micelles (NC-6004) in Patients with Solid Tumors

BACKGROUND: On the basis of preclinical studies of NC-6004, a cisplatin-incorporated micellar formulation, we hypothesised that NC-6004 could show lower toxicity than cisplatin and show greater anti-tumour activity in phase I study. METHODS: A total of 17 patients were recruited in a range of advanced solid tumour types. NC-6004 was administered intravenously (i.v.) every 3 weeks. The dose escalation started at 10?mg?m(-2) and was increased up to 120?mg?m(-2) according to the accelerated titration method and modified Fibonacci method. RESULTS: One dose-limiting toxicity (DLT) occurred in a patient who was given 90?mg?m(-2) of NC-6004, otherwise any significant cisplatin-related toxicity was not observed or generally mild toxicity was observed. Despite the implementation of post-hydration and pre-medication regimen, renal impairment and hypersensitivity reactions still developed at 120?mg?m(-2), which led to the conclusion that the maximum tolerated dose was 120?mg?m(-2), and the recommended dose was 90?mg?m(-2), although DLT was not defined as per protocol. Stable disease was observed in seven patients. The maximum concentration and area under the concentration-time curve of ultrafilterable platinum at 120?mg?m(-2) NC-6004 were 34-fold smaller and 8.5-fold larger, respectively, than those for cisplatin. CONCLUSION: The delayed and sustained release of cisplatin after i.v. administration contributes to the low toxicity of NC-6004.

Letter, Greensboro, NC, to George Washington Spencer, Chesterfield, SC, 1890 January 11

This letter is from G. W. Winstead and A. M. Scales to G. W. Spencer regarding Reverend Dr. J. W. Blosser.

Letter, Wadesboro, NC, to Oliver Hawes Spencer, Cheraw, SC, 1811 January 15

This letter is to O. H. Spencer.

Letter, Cedar Hill, NC, to Oliver Hawes Spencer, Cheraw, SC, 1842 November 3

This letter is to O. H. Spencer.